Frataxin deficiency leads to defects in expression of antioxidants and Nrf2 expression in dorsal root ganglia of the Friedreich's Ataxia YG8R mouse model

Antioxidants and Redox Signaling

Volumn 19, Issue 13, 2013, Pages 1481-1493

  Shan, Yuxi ^a   Schoenfeld, Robert A ^a   Hayashi, Genki ^a   Napoli, Eleonora ^a   Akiyama, Tasuku ^a   Iodi Carstens, Mirela ^a   Carstens, Earl E ^a   Pook, Mark A ^b   Cortopassi, Gino A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRUNEL UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; AURANOFIN; FRATAXIN; GLUTAREDOXIN; GLUTATHIONE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; KINESIN 1; KINESIN 5; PEROXIREDOXIN 3; THIOREDOXIN REDUCTASE; TRANSCRIPTION FACTOR NRF2; IRON BINDING PROTEIN; NFE2L2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ARTICLE; CELL NUCLEUS; CEREBELLUM; CYTOSOL; ENZYME ACTIVITY; FRIEDREICH ATAXIA; GENOTYPE; GLUTATHIONE METABOLISM; IMMUNOBLOTTING; MOUSE; NERVE FIBER TRANSPORT; NEURITE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SPINAL GANGLION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; DISEASE MODEL; GENETICS; HELA CELL LINE; HUMAN; METABOLISM; RAT;

EPICOCCUM; MUS;

ANIMALS; ANTIOXIDANTS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FRIEDREICH ATAXIA; GANGLIA, SPINAL; HELA CELLS; HUMANS; IRON-BINDING PROTEINS; MICE; MICE, INBRED C57BL; NF-E2-RELATED FACTOR 2; RATS;

EID: 84876314544     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2012.4537     Document Type: Article

References (81)

1. Abramoff MD, Magalhaes PJ, and Ram SJ. Image Processing with ImageJ. Biophotonics Int 11: 36-42, 2004.
2. Adair-Kirk TL, Atkinson JJ, Griffin GL, Watson MA, Kelley DG, DeMelloD, Senior RM, and Betsuyaku T. Distal airways in mice exposed to cigarette smoke: Nrf2-regulated genes are increased in Clara cells. Am J Respir CellMol Biol 39: 400-411, 2008.
3. Al-Mahdawi S, Pinto RM, Ruddle P, Carroll C, Webster Z, and Pook M. GAA repeat instability in Friedreich ataxia YAC transgenic mice. Genomics 84: 301-310, 2004.
4. Al-Mahdawi S, Pinto RM, Varshney D, Lawrence L, Lowrie MB, Hughes S, Webster Z, Blake J, Cooper JM, King R, and Pook MA. GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology. Genomics 88: 580-590, 2006.
5. Anderson PR, Kirby K, Hilliker AJ, and Phillips JP. RNAimediated suppression of the mitochondrial iron chaperone, frataxin, in Drosophila. Hum Mol Genet 14: 3397-3405, 2005.
6. Anderson PR, Kirby K, Orr WC, Hilliker AJ, and Phillips JP. Hydrogen peroxide scavenging rescues frataxin deficiency in a Drosophila model of Friedreich's ataxia. Proc Natl Acad Sci USA 105: 611-616, 2008.
7. Auchere F, Santos R, Planamente S, Lesuisse E, and Camadro JM. Glutathione-dependent redox status of frataxindeficient cells in a yeast model of Friedreich's ataxia. Hum Mol Genet 17: 2790-2802, 2008.
8. Bannister JV, Bannister WH, and Rotilio G. Aspects of the structure, function, and applications of superoxide dismutase. CRC Crit Rev Biochem 22: 111-180, 1987.
9. Benomar A, Yahyaoui M, Meggouh F, Bouhouche A, Boutchich M, Bouslam N, Zaim A, Schmitt M, Belaidi H, Ouazzani R, Chkili T, and Koenig M. Clinical comparison between AVED patients with 744 del A mutation and Friedreich ataxia with GAA expansion in 15 Moroccan families. J Neurol Sci 198: 25-29, 2002.
10. Bradley JL, Blake JC, Chamberlain S, Thomas PK, Cooper JM, and Schapira AH. Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. Hum Mol Genet 9: 275-282, 2000.
11. Bridwell-Rabb J, Winn AM, and Barondeau DP. Structurefunction analysis of friedreich's ataxia mutants reveals determinants of frataxin binding and activation of the Fe-S assembly complex. Biochemistry 50: 7265-7274, 2011.
12. Bulteau AL, Dancis A, Gareil M, Montagne JJ, Camadro JM, and Lesuisse E. Oxidative stress and protease dysfunction in the yeast model of Friedreich ataxia. Free Radic Biol Med 42: 1561-1570, 2007.
13. Bulteau AL, Planamente S, Jornea L, Dur A, Lesuisse E, Camadro JM, and Auchere F. Changes in mitochondrial glutathione levels and protein thiol oxidation in yfh1 yeast cells and the lymphoblasts of patients with Friedreich's ataxia. Biochim Biophys Acta 1822: 212-225, 2012.
14. Calabrese V, Lodi R, Tonon C, D'Agata V, Sapienza M, Scapagnini G, Mangiameli A, Pennisi G, Stella AM, and Butterfield DA. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia. J Neurol Sci 233: 145-162, 2005.
15. Calkins MJ, Johnson DA, Townsend JA, Vargas MR, Dowell JA,Williamson TP, Kraft AD, Lee JM, Li J, and Johnson JA. The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease. Antioxid Redox Signal 11: 497-508, 2009.
16. Campuzano V, Montermini L, Lutz Y, Cova L, Hindelang C, Jiralerspong S, Trottier Y, Kish SJ, Faucheux B, Trouillas P, Authier FJ, Durr A, Mandel JL, Vescovi A, Pandolfo M, and Koenig M. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet 6: 1771-1780, 1997.
17. Campuzano V, Montermini L, Molto MD, Pianese L, Cossee M, Cavalcanti F, Monros E, Rodius F, Duclos F, Monticelli A, Zara F, Canizares J, Koutnikova H, Bidichandani SI, Gellera C, Brice A, Trouillas P, De Michele G, Filla A, De Frutos R, Palau F, Patel PI, Di Donato S, Mandel JL, Cocozza S, Koenig M, and Pandolfo M. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271: 1423-1427, 1996.
18. Chantrel-Groussard K, Geromel V, Puccio H, Koenig M, Munnich A, Rotig A, and Rustin P. Disabled early recruitment of antioxidant defenses in Friedreich's ataxia. Hum Mol Genet 10: 2061-2067, 2001.
19. Chao PL, Fan SF, Chou YH, and Lin AM. N-acetylcysteine attenuates arsenite-induced oxidative injury in dorsal root ganglion explants. Ann N Y Acad Sci 1122: 276-288, 2007.
20. Chelikani P, Fita I, and Loewen PC. Diversity of structures and properties among catalases. Cell Mol Life Sci 61: 192-208, 2004.
21. Cossee M, Puccio H, Gansmuller A, Koutnikova H, Dierich A, LeMeur M, Fischbeck K, Dolle P, and Koenig M. Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum Mol Genet 9: 1219-1226, 2000.
22. Cox AG, Brown KK, Arner ES, and Hampton MB. The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation. Biochem Pharmacol 76: 1097-1109, 2008.
23. Dardalhon M, Kumar C, Iraqui I, Vernis L, Kienda G, Banach-Latapy A, He T, Chanet R, Faye G, Outten CE, and Huang ME. Redox-sensitive YFP sensors monitor dynamic nuclear and cytosolic glutathione redox changes. Free Radic Biol Med 52: 2254-2265, 2012.
24. DasKCandWhiteCW.Redox systemsof the cell: possible links and implications. Proc Natl Acad Sci USA 99: 9617-9618, 2002.
25. Durr A, Cossee M, Agid Y, Campuzano V, Mignard C, Penet C, Mandel JL, Brice A, and Koenig M. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med 335: 1169-1175, 1996.
26. Emond M, Lepage G, Vanasse M, and Pandolfo M. Increased levels of plasma malondialdehyde in Friedreich ataxia. Neurology 55: 1752-1753, 2000.
27. Feng Z, Liu Z, Li X, Jia H, Sun L, Tian C, Jia L, and Liu J. alpha-Tocopherol is an effective Phase II enzyme inducer: protective effects on acrolein-induced oxidative stress and mitochondrial dysfunction in human retinal pigment epithelial cells. J Nutr Biochem 21: 1222-1231, 2010.
28. Filla A, De Michele G, Cavalcanti F, Pianese L, Monticelli A, Campanella G, and Cocozza S. The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am J Hum Genet 59: 554-560, 1996.
29. Finocchiaro G, Baio G, Micossi P, Pozza G, and di Donato S. Glucose metabolism alterations in Friedreich's ataxia. Neurology 38: 1292-1296, 1988.
30. Gromer S, Arscott LD, Williams CH, Jr., Schirmer RH, and Becker K.Humanplacenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J Biol Chem273: 20096-20101, 1998.
31. Harding AE and Hewer RL. The heart disease of Friedreich's ataxia: a clinical and electrocardiographic study of 115 patients, with an analysis of serial electrocardiographic changes in 30 cases. Q J Med 52: 489-502, 1983.
32. Haugen AC, Di Prospero NA, Parker JS, Fannin RD, Chou J, Meyer JN, Halweg C, Collins JB, Durr A, Fischbeck K, and Van Houten B. Altered gene expression and DNA damage in peripheral blood cells from Friedreich's ataxia patients: cellular model of pathology. PLoS Genet 6: e1000812, 2010.
33. Hirokawa N and Noda Y. Intracellular transport and kinesin superfamily proteins, KIFs: structure, function, and dynamics. Physiol Rev 88: 1089-1118, 2008.
34. Ilieva H, Polymenidou M, and Cleveland DW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol 187: 761-772, 2009.
35. Innamorato NG, Rojo AI, Garcia-Yague AJ, Yamamoto M, de Ceballos ML, and Cuadrado A. The transcription factor Nrf2 is a therapeutic target against brain inflammation. J Immunol 181: 680-689, 2008.
36. Jauslin ML, Wirth T, Meier T, and Schoumacher F. A cellular model for Friedreich Ataxia reveals small-molecule glutathione peroxidase mimetics as novel treatment strategy. Hum Mol Genet 11: 3055-3063, 2002.
37. Kalinina EV, Chernov NN, and Saprin AN. Involvement of thio-, peroxi-, and glutaredoxins in cellular redox-dependent processes. Biochemistry (Mosc) 73: 1493-1510, 2008.
38. Koeppen AH, Michael SC, Knutson MD, Haile DJ, Qian J, Levi S, Santambrogio P, Garrick MD, and Lamarche JB. The dentate nucleus in Friedreich's ataxia: the role of ironresponsive proteins. Acta Neuropathol 114: 163-173, 2007.
39. Koeppen AH, Morral JA, Davis AN, Qian J, Petrocine SV, Knutson MD, Gibson WM, Cusack MJ, and Li D. The dorsal root ganglion in Friedreich's ataxia. Acta Neuropathol 118: 763-776, 2009.
40. Kollberg G, Tulinius M, Melberg A, Darin N, Andersen O, Holmgren D, Oldfors A, and Holme E. Clinical manifestation and a new ISCU mutation in iron-sulphur cluster deficiency myopathy. Brain 132: 2170-2179, 2009.
41. Kong L, Tanito M, Huang Z, Li F, Zhou X, Zaharia A, Yodoi J, McGinnis JF, and Cao W. Delay of photoreceptor degeneration in tubby mouse by sulforaphane. J Neurochem 101: 1041-1052, 2007.
42. Kwak MK, Wakabayashi N, Itoh K, Motohashi H, Yamamoto M, and Kensler TW. Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J Biol Chem 278: 8135-8145, 2003.
43. Lefevre S, Brossas C, Auchere F, Boggetto N, Camadro JM, and Santos R. Apn1 AP-endonuclease is essential for the repair of oxidatively damaged DNA bases in yeast frataxindeficient cells. Hum Mol Genet 21: 4060-4072, 2012.
44. Li H and Outten CE. Monothiol CGFS Glutaredoxins and BolA-like Proteins: [2Fe-2S] Binding Partners in Iron Homeostasis. Biochemistry 51: 4377-4389, 2012.
45. Lu C, Schoenfeld R, Shan Y, Tsai HJ, Hammock B, and Cortopassi G. Frataxin deficiency induces Schwann cell inflammation and death. Biochim Biophys Acta 1792: 1052-1061, 2009.
46. Maher P. Redox control of neural function: background, mechanisms, and significance. Antioxid Redox Signal 8: 1941-1970, 2006.
47. McMahon M, Lamont DJ, Beattie KA, and Hayes JD. Keap1 perceives stress via three sensors for the endogenous signaling molecules nitric oxide, zinc, and alkenals. Proc Natl Acad Sci USA 107: 18838-18843, 2010.
48. Meijering E, Jacob M, Sarria JC, Steiner P, Hirling H, and Unser M. Design and validation of a tool for neurite tracing and analysis in fluorescence microscopy images. Cytometry A 58: 167-176, 2004.
49. Mochel F, Knight MA, Tong WH, Hernandez D, Ayyad K, Taivassalo T, Andersen PM, Singleton A, Rouault TA, Fischbeck KH, and Haller RG. Splice mutation in the ironsulfur cluster scaffold protein ISCU causes myopathy with exercise intolerance. Am J Hum Genet 82: 652-660, 2008.
50. Montermini L, Richter A, Morgan K, Justice CM, Julien D, Castellotti B, Mercier J, Poirier J, Capozzoli F, Bouchard JP, Lemieux B, Mathieu J, Vanasse M, Seni MH, Graham G, Andermann F, Andermann E, Melancon SB, Keats BJ, Di Donato S, and Pandolfo M. Phenotypic variability in Friedreich ataxia: role of the associated GAA triplet repeat expansion. Ann Neurol 41: 675-682, 1997.
51. Nguyen T, Sherratt PJ, Nioi P, Yang CS, and Pickett CB. Nrf2 controls constitutive and inducible expression of ARE-driven genes through a dynamic pathway involving nucleocytoplasmic shuttling by Keap1. J Biol Chem 280: 32485-32492, 2005.
52. Njalsson R and Norgren S. Physiological and pathological aspects of GSH metabolism. Acta Paediatr 94: 132-137, 2005.
53. Pastore A, Tozzi G, Gaeta LM, Bertini E, Serafini V, Di Cesare S, Bonetto V, Casoni F, Carrozzo R, Federici G, and Piemonte F. Actin glutathionylation increases in fibroblasts of patients with Friedreich's ataxia: a potential role in the pathogenesis of the disease. J Biol Chem 278: 42588-42595, 2003.
54. Patel VP and Chu CT. Nuclear transport, oxidative stress, and neurodegeneration. Int J Clin Exp Pathol 4: 215-229, 2011.
55. Paupe V, Dassa EP, Goncalves S, Auchere F, Lonn M, Holmgren A, and Rustin P. Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia. PLoS One 4: e4253, 2009.
56. Piemonte F, Pastore A, Tozzi G, Tagliacozzi D, Santorelli FM, Carrozzo R, Casali C, Damiano M, Federici G, and Bertini E. Glutathione in blood of patients with Friedreich's ataxia. Eur J Clin Invest 31: 1007-1011, 2001.
57. Pompella A, Visvikis A, Paolicchi A, De Tata V, and Casini AF. The changing faces of glutathione, a cellular protagonist. Biochem Pharmacol 66: 1499-1503, 2003.
58. Pondarre C, Campagna DR, Antiochos B, Sikorski L, Mulhern H, and Fleming MD. Abcb7, the gene responsible for Xlinked sideroblastic anemia with ataxia, is essential for hematopoiesis. Blood 109: 3567-3569, 2007.
59. Puccio H, Simon D, Cossee M, Criqui-Filipe P, Tiziano F, Melki J, Hindelang C, Matyas R, Rustin P, and Koenig M. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet 27: 181-186, 2001.
60. Radisky DC, Babcock MC, and Kaplan J. The yeast frataxin homologue mediates mitochondrial iron efflux. Evidence for a mitochondrial iron cycle. J Biol Chem 274: 4497-4499, 1999.
61. Ristow M, Mulder H, Pomplun D, Schulz TJ, Muller-Schmehl K, Krause A, Fex M, Puccio H, Muller J, Isken F, Spranger J, Muller-Wieland D, Magnuson MA, Mohlig M, Koenig M, and Pfeiffer AF. Frataxin deficiency in pancreatic islets causes diabetes due to loss of beta cell mass. J Clin Invest 112: 527-534, 2003.
62. Rosen DR. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 364: 362, 1993.
63. Rotig A, de Lonlay P, Chretien D, Foury F, Koenig M, Sidi D, Munnich A, and Rustin P. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet 17: 215-217, 1997.
64. Runko AP, Griswold AJ, and Min KT. Overexpression of frataxin in the mitochondria increases resistance to oxidative stress and extends lifespan in Drosophila. FEBS Lett 582: 715-719, 2008.
65. Schadt EE, Li C, Ellis B, and Wong WH. Feature extraction and normalization algorithms for high-density oligonucleotide gene expression array data. J Cell Biochem Suppl Suppl 37: 120-125, 2001.
66. Schmucker S, Martelli A, Colin F, Page A, Wattenhofer-Donze M, Reutenauer L, and Puccio H. Mammalian frataxin: an essential function for cellular viability through an interaction with a preformed ISCU/NFS1/ISD11 iron-sulfur assembly complex. PLoS One 6: e16199, 2011.
67. Schulz JB, Dehmer T, Schols L, Mende H, Hardt C, Vorgerd M, Burk K, Matson W, Dichgans J, Beal MF, and Bogdanov MB. Oxidative stress in patients with Friedreich ataxia. Neurology 55: 1719-1721, 2000.
68. Shan Y, Napoli E, and Cortopassi G. Mitochondrial frataxin interacts with ISD11 of the NFS1/ISCU complex and multiple mitochondrial chaperones. Hum Mol Genet 16: 929-941, 2007.
69. Shidara Y and Hollenbeck PJ. Defects in mitochondrial axonal transport and membrane potential without increased reactive oxygen species production in a Drosophila model of Friedreich ataxia. J Neurosci 30: 11369-11378, 2010.
70. Shih AY, Johnson DA, Wong G, Kraft AD, Jiang L, Erb H, Johnson JA, and Murphy TH. Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J Neurosci 23: 3394-3406, 2003.
71. Sparaco M, Gaeta LM, Santorelli FM, Passarelli C, Tozzi G, Bertini E, Simonati A, Scaravilli F, Taroni F, Duyckaerts C, Feleppa M, and Piemonte F. Friedreich's ataxia: oxidative stress and cytoskeletal abnormalities. J Neurol Sci 287: 111-118, 2009.
72. Stehling O, Elsasser HP, Bruckel B, Muhlenhoff U, and Lill R. Iron-sulfur protein maturation in human cells: evidence for a function of frataxin. Hum Mol Genet 13: 3007-3015, 2004.
73. Tan G, Napoli E, Taroni F, and Cortopassi G. Decreased expression of genes involved in sulfur amino acid metabolism in frataxin-deficient cells. Hum Mol Genet 12: 1699-1711, 2003.
74. Thierbach R, Schulz TJ, Isken F, Voigt A, Mietzner B, Drewes G, von Kleist-Retzow JC, Wiesner RJ, Magnuson MA, Puccio H, Pfeiffer AF, Steinberg P, and Ristow M. Targeted disruption of hepatic frataxin expression causes impaired mitochondrial function, decreased life span and tumor growth in mice. Hum Mol Genet 14: 3857-3864, 2005.
75. Traber MG and Atkinson J. Vitamin E, antioxidant and nothing more. Free Radic Biol Med 43: 4-15, 2007.
76. Varija D, Kumar KP, Reddy KP, and Reddy VK. Prolonged constriction of sciatic nerve affecting oxidative stressors & antioxidant enzymes in rat. Indian J Med Res 129: 587-592, 2009.
77. Vazquez-Manrique RP, Gonzalez-Cabo P, Ros S, Aziz H, Baylis HA, and Palau F. Reduction of Caenorhabditis elegans frataxin increases sensitivity to oxidative stress, reduces lifespan, and causes lethality in a mitochondrial complex II mutant. FASEB J 20: 172-174, 2006.
78. Wong A, Yang J, Cavadini P, Gellera C, Lonnerdal B, Taroni F, and Cortopassi G. The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum Mol Genet 8: 425-430, 1999.
79. Wong A, Yang J, Danielson S, Gellera C, Taroni F, and Cortopassi G. Sensitivity of FRDA lymphoblasts to salts of transition metal ions. Antioxid Redox Signal 2: 461-465, 2000.
80. Wu KC, Cui JY, and Klaassen CD. Beneficial role of Nrf2 in regulating NADPH generation and consumption. Toxicol Sci 123: 590-600, 2011.
81. Ye H, Jeong SY, Ghosh MC, Kovtunovych G, Silvestri L, Ortillo D, Uchida N, Tisdale J, Camaschella C, and Rouault TA. Glutaredoxin 5 deficiency causes sideroblastic anemia by specifically impairing heme biosynthesis and depleting cytosolic iron in human erythroblasts. J Clin Invest 120: 1749-1761, 2010.